260 related articles for article (PubMed ID: 8339287)
21. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
[TBL] [Abstract][Full Text] [Related]
22. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1).
Woo JH; Bour SH; Dang T; Lee YJ; Park SK; Andreas E; Kang SH; Liu JS; Neville DM; Frankel AE
Cancer Immunol Immunother; 2008 Aug; 57(8):1225-39. PubMed ID: 18256829
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration.
Bergman I; Burckart GJ; Pohl CR; Venkataramanan R; Barmada MA; Griffin JA; Cheung NK
J Pharmacol Exp Ther; 1998 Jan; 284(1):111-5. PubMed ID: 9435168
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of human subconjunctival fibroblast proliferation by immunotoxin.
Wilkerson M; Fulcher S; Shields MB; Foulks GN; Hatchell DL; Houston LL
Invest Ophthalmol Vis Sci; 1992 Jun; 33(7):2293-8. PubMed ID: 1607241
[TBL] [Abstract][Full Text] [Related]
27. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.
Gonzalez R; Salem P; Bunn PA; Zukiwski AA; Lamb R; Benjamin RS; Spitler L; Wedel N; Robinson WA
Mol Biother; 1991 Dec; 3(4):192-6. PubMed ID: 1768370
[TBL] [Abstract][Full Text] [Related]
28. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
[TBL] [Abstract][Full Text] [Related]
29. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
Zovickian J; Johnson VG; Youle RJ
J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody.
Wu D; Pardridge WM
Drug Metab Dispos; 1998 Sep; 26(9):937-9. PubMed ID: 9733674
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice.
Laske DW; Ilercil O; Akbasak A; Youle RJ; Oldfield EH
J Neurosurg; 1994 Mar; 80(3):520-6. PubMed ID: 8113865
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys, and humans.
Olsen GW; Chang SC; Noker PE; Gorman GS; Ehresman DJ; Lieder PH; Butenhoff JL
Toxicology; 2009 Feb; 256(1-2):65-74. PubMed ID: 19059455
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
Uckun FM; Yanishevski Y; Tumer N; Waurzyniak B; Messinger Y; Chelstrom LM; Lisowski EA; Ek O; Zeren T; Wendorf H; Langlie MC; Irvin JD; Myers DE; Fuller GB; Evans W; Gunther R
Clin Cancer Res; 1997 Mar; 3(3):325-37. PubMed ID: 9815689
[TBL] [Abstract][Full Text] [Related]
34. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
Blakey DC; Watson GJ; Knowles PP; Thorpe PE
Cancer Res; 1987 Feb; 47(4):947-52. PubMed ID: 3492271
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of human corneal epithelium with immunotoxin 454A12-rRA.
Fulcher SF; Foulks GN; Wilkerson M; Cobo LM; Jaffe GJ; Hatchell DL
Cornea; 1992 Sep; 11(5):413-7. PubMed ID: 1424670
[TBL] [Abstract][Full Text] [Related]
36. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
[TBL] [Abstract][Full Text] [Related]
37. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates.
Berg SL; Aleksic A; McGuffey L; Dauser R; Nuchtern J; Bernacky B; Blaney SM
Cancer Chemother Pharmacol; 2004 Aug; 54(2):127-30. PubMed ID: 15150671
[TBL] [Abstract][Full Text] [Related]
38. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
Waurzyniak B; Schneider EA; Tumer N; Yanishevski Y; Gunther R; Chelstrom LM; Wendorf H; Myers DE; Irvin JD; Messinger Y; Ek O; Zeren T; Langlie MC; Evans WE; Uckun FM
Clin Cancer Res; 1997 Jun; 3(6):881-90. PubMed ID: 9815763
[TBL] [Abstract][Full Text] [Related]
39. Biodistribution of ricin toxin A chain-monoclonal antibody 791T/36 immunotoxin and influence of hepatic blocking agents.
Byers VS; Pimm MV; Pawluczyk IZ; Lee HM; Scannon PJ; Baldwin RW
Cancer Res; 1987 Oct; 47(20):5277-83. PubMed ID: 3498532
[TBL] [Abstract][Full Text] [Related]
40. Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats.
Sun JM; Nam MH; Chung JY; Im B; Lee SY; Suh YL; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2011 Aug; 68(2):531-8. PubMed ID: 21107572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
